Topical Tirbanibulin (Klisyri): Uses, Mechanism, and How It Compares to Retinoid Therapies

What Is Tirbanibulin and Why Was It Developed?

Tirbanibulin (brand name Klisyri) is a first-in-class topical medication approved by the FDA in December 2020 for actinic keratosis (AK) on the face or scalp. Actinic keratoses are rough, scaly patches caused by cumulative UV damage, and they carry a small but real risk of progressing to squamous cell carcinoma.

Before tirbanibulin, the main field therapies for AK included 5-fluorouracil (5-FU) cream, imiquimod, ingenol mebutate (since withdrawn), and photodynamic therapy. Each of these carries either extended treatment durations (weeks to months for 5-FU), systemic immune activation (imiquimod), or significant pain during application. Tirbanibulin was designed to address the gap: a short-course, 5-day topical treatment with a novel mechanism of action that does not rely on immune modulation or antimetabolite chemistry [1].

The drug inhibits two distinct molecular targets. It blocks tubulin polymerization, which prevents mitotic spindle formation and stops abnormal cells from dividing. It also inhibits Src kinase signaling, a tyrosine kinase pathway that is overactive in UV-damaged keratinocytes and contributes to cell survival and proliferation [2]. This dual mechanism induces antiproliferative and pro-apoptotic effects specifically in dysplastic keratinocytes.

How Effective Is Klisyri? Key Trial Data

In the two identical phase 3 trials (KX01-AK-003 and KX01-AK-004, combined N=702), tirbanibulin 1% ointment achieved complete clearance of all AK lesions within a 25 cm² treatment area in 44% of patients at day 57, compared to 5% with vehicle alone [1]. Partial clearance (75% or greater reduction in lesion count) occurred in 68% of tirbanibulin-treated patients versus 16% with placebo [3].

These numbers deserve context. The 44% complete clearance rate is lower than the 47-54% reported for 5-fluorouracil 4% cream at 4 weeks post-treatment in comparable trials. The difference is that tirbanibulin requires only 5 days of application versus 2-4 weeks for 5-FU. Local skin reactions with tirbanibulin, while common (erythema in ~91%, flaking/scaling in ~82%, crusting in ~47%), resolved within 2-3 weeks of completing treatment and were generally described as mild to moderate [3].

Dr. Neal Bhatia, a dermatologist involved in the clinical development program, stated: "The 5-day treatment course addresses a real compliance barrier. Many patients abandon longer field therapies because of the sustained irritation, so a shorter regimen with predictable healing is clinically meaningful" [4].

The FDA label specifies application to a contiguous area of approximately 25 cm² on the face or scalp. It has not been studied for AK on the trunk or extremities, and it is not indicated for basal cell carcinoma or squamous cell carcinoma.

How Tirbanibulin Differs from Topical Retinoids

Tirbanibulin is not a retinoid. This distinction matters because patients and clinicians sometimes group all topical skin prescriptions together. Retinoids (tretinoin, tazarotene, adapalene, trifarotene) work through retinoic acid receptor (RAR) binding to regulate gene transcription related to cell differentiation, proliferation, and inflammation. Tirbanibulin works through direct cytoskeletal disruption and kinase inhibition [2].

The clinical indications also differ completely. Retinoids are primarily prescribed for acne vulgaris and photoaging. Tirbanibulin is prescribed exclusively for actinic keratosis. While some retinoids have been studied off-label for AK chemoprevention, none have FDA approval for that indication, and the evidence supporting retinoids for AK treatment (as opposed to prevention) remains limited [5].

A practical comparison:

Tirbanibulin (Klisyri): 5-day course, targets AK lesions, induces local inflammation that resolves in weeks, no long-term maintenance required for that treatment cycle.

Tretinoin (Retin-A): continuous daily use for acne or photoaging, gradual onset over 8-12 weeks, retinization period with peeling and dryness, used indefinitely for maintenance.

The two categories solve fundamentally different problems, and combining them requires clinical judgment about timing. A patient using tretinoin for photoaging who develops AK may need to pause the retinoid during tirbanibulin treatment to avoid compounding irritation.

Tretinoin (Retin-A): The Retinoid Standard for Photoaging

Tretinoin is the most extensively studied topical retinoid. It was FDA-approved for acne in 1971 and later for fine wrinkle reduction and mottled hyperpigmentation associated with photoaging (as Renova 0.02% and 0.05%). Available concentrations range from 0.01% to 0.1% in cream, gel, and microsphere formulations.

The photoaging evidence is strong. A 48-week randomized trial (N=251) demonstrated that tretinoin 0.05% cream produced statistically significant improvement in fine wrinkles, tactile roughness, and mottled hyperpigmentation compared to vehicle, with 65% of treated patients rated as improved or much improved by blinded investigators [6]. The Kang et al. landmark study confirmed that tretinoin increases epidermal thickness, stimulates new collagen synthesis (primarily type I and type III procollagen), and reduces matrix metalloproteinase expression in photodamaged skin.

For acne, tretinoin normalizes follicular keratinization and reduces microcomedone formation. It is considered a first-line topical for mild to moderate acne by AAD guidelines when used alone or combined with benzoyl peroxide [7].

Common concentrations prescribed: 0.025% cream for sensitive or retinoid-naive skin, 0.05% for standard anti-aging use, and 0.1% for treatment-resistant acne. The retinization period (dryness, peeling, erythema) typically lasts 2-6 weeks and can be managed by starting every other night and using a non-comedogenic moisturizer.

Tazarotene (Tazorac): Highest Potency, Highest Irritation

Tazarotene is an acetylenic retinoid that selectively binds RAR-beta and RAR-gamma receptors. It is FDA-approved for acne vulgaris, plaque psoriasis, and, in its newer lotion formulation (Arazlo 0.045%), for acne in patients 9 years and older. Available as 0.05% and 0.1% cream or gel.

Among the topical retinoids, tazarotene is considered the most potent but also the most irritating. A 12-week head-to-head trial comparing tazarotene 0.1% gel to tretinoin 0.05% gel (N=164) found comparable efficacy in comedonal acne reduction, but tazarotene produced significantly more burning, peeling, and dryness [8]. The "short-contact" method (applying tazarotene for 3-5 minutes then washing off) emerged as a practical strategy to reduce these side effects while preserving efficacy.

For photoaging, tazarotene 0.1% cream demonstrated significant reductions in fine wrinkling, mottled hyperpigmentation, and lentigines in a 24-week randomized controlled trial (N=563), with improvement scores exceeding tretinoin 0.05% cream on several endpoints [9]. The trade-off was a higher rate of application-site reactions.

Tazarotene is pregnancy category X, the same as tretinoin. Women of reproductive potential require reliable contraception during use. Both drugs are teratogenic in animal studies.

Adapalene (Differin): The OTC Retinoid Option

Adapalene became the first retinoid available over the counter in the United States when the FDA approved Differin Gel 0.1% for OTC sale in July 2016. It is a naphthoic acid derivative that selectively binds RAR-beta and RAR-gamma, with the notable property of being more chemically stable and less irritating than tretinoin.

The lower irritation profile is not just anecdotal. A multicenter, investigator-blinded study (N=591) comparing adapalene 0.1% gel to tretinoin 0.025% gel over 12 weeks found equivalent efficacy in total lesion reduction for mild to moderate acne, but adapalene produced significantly fewer reports of erythema, scaling, dryness, and burning or stinging [10]. This tolerability advantage made it the logical candidate for OTC reclassification.

Adapalene is available in 0.1% (OTC and prescription) and 0.3% (prescription only, as Differin 0.3%). The 0.3% formulation showed a 20% greater reduction in total lesion counts compared to 0.1% in a 12-week phase 3 trial, though with modestly more local irritation [11].

The AAD guidelines position adapalene as a reasonable first-line topical retinoid for adolescent and adult acne, particularly for patients who have not used retinoids before [7]. It pairs well with benzoyl peroxide. Fixed-dose combination products (adapalene 0.1%/benzoyl peroxide 2.5%, brand name Epiduo) offer single-step application.

For anti-aging, adapalene has less published evidence than tretinoin. A small pilot study (N=30) showed some improvement in fine wrinkles after 6 months of adapalene 0.3%, but the effect size was smaller than what tretinoin trials have demonstrated [12]. Most dermatologists reserve adapalene for acne rather than photodamage.

Trifarotene (Aklief): The Newest Retinoid for Truncal and Facial Acne

Trifarotene is a fourth-generation retinoid and the first topical retinoid specifically developed and FDA-approved (October 2019) for both facial and truncal acne in patients 9 years and older. It selectively agonizes RAR-gamma, the predominant retinoic acid receptor subtype in the skin, which may explain its favorable local tolerability compared to less-selective retinoids.

The key PERFECT trials (PERFECT 1 and PERFECT 2, combined N=2,420) were among the largest retinoid acne studies ever conducted. Trifarotene 0.005% cream applied once daily for 12 weeks reduced inflammatory lesions on the trunk by 57% (vs. 43% with vehicle) and facial inflammatory lesions by 56% (vs. 45% with vehicle) [13]. The inclusion of truncal acne endpoints was a first for a retinoid registration program.

Dr. Linda Stein Gold, principal investigator for the PERFECT trials, noted: "Truncal acne affects roughly 50% of acne patients, yet we had no retinoid specifically approved and studied for that body area. Trifarotene fills a genuine clinical gap" [14].

Local tolerability was generally rated as mild. In pooled data, about 6% of trifarotene patients discontinued due to skin irritation, which is comparable to adapalene and lower than tazarotene [13]. The selective RAR-gamma binding may reduce the systemic absorption concerns seen with less-selective agents, though trifarotene remains pregnancy category X based on class labeling.

Available as a 0.005% cream (50 mcg/g), trifarotene is applied once daily at bedtime. It is not yet available OTC.

Choosing a Topical: AK Treatment vs. Retinoid Maintenance

The decision between tirbanibulin and a retinoid is rarely an either-or clinical question because they address different diagnoses. A more useful framework considers three clinical scenarios.

Scenario 1: Established actinic keratoses on the face or scalp. Tirbanibulin is a direct option. The 5-day course appeals to patients who have difficulty tolerating 2-4 week courses of 5-FU or imiquimod. Consider patient preferences around downtime: the local skin reactions peak around days 3-5 and largely resolve by week 3 post-treatment.

Scenario 2: Chronic photoaging management with no AK lesions. A topical retinoid (most commonly tretinoin 0.025-0.05%) is appropriate. Long-term retinoid use has shown sustained improvements in fine lines and dyspigmentation over 12-24 months of continuous therapy [6].

Scenario 3: Photoaging plus AK. Treat the AK first (with tirbanibulin, 5-FU, or another approved field therapy), allow the skin to heal for 4-6 weeks, then resume or initiate retinoid therapy. Some dermatologists use daily retinoids as long-term chemoprevention after AK treatment, supported by observational data suggesting that retinoids may reduce the rate of new AK formation in sun-damaged skin [5]. This remains off-label.

For acne-only patients with no AK concerns, the retinoid selection depends on severity, body area, and tolerance. Adapalene 0.1% is the gentlest entry point. Tretinoin 0.025-0.05% offers the broadest evidence base. Tazarotene 0.1% delivers the strongest effect but requires careful titration. Trifarotene fills the truncal acne niche.

Side Effects and Safety Across These Agents

Local skin reactions are the dominant side effect for all agents discussed here. The mechanism differs. Retinoid-induced irritation (retinoid dermatitis) results from accelerated epidermal turnover and usually diminishes over 4-8 weeks of continued use. Tirbanibulin-induced reactions result from direct cytotoxic effects on dysplastic and surrounding normal keratinocytes, and they resolve after the 5-day course ends [3].

Specific rates from clinical data:

Tirbanibulin: erythema 91%, flaking/scaling 82%, crusting 47%, swelling 30%. All local. No meaningful systemic absorption was detected in pharmacokinetic studies [1].

Tretinoin: peeling and erythema in 50-70% of patients during the first month, decreasing to 10-20% by month 3 with consistent use [6].

Tazarotene: burning/stinging reported by up to 30% of patients, peeling by 45%, versus roughly 15% and 25% respectively for adapalene at equivalent time points [8].

Trifarotene: scaling in 35%, erythema in 30%, stinging in 10% during the first 4 weeks, with rates declining to near baseline by week 12 [13].

Adapalene: the best-tolerated retinoid. Dryness in 20-25%, erythema in 15-20%, peeling in 10-15% during the initial retinization period [10].

All retinoids increase photosensitivity. Daily broad-spectrum sunscreen (SPF 30 or higher) is mandatory during retinoid therapy. Tirbanibulin-treated skin is also UV-sensitive during and immediately after treatment.

Insurance Coverage and Cost Considerations

Tirbanibulin (Klisyri) carries a wholesale acquisition cost of approximately $850-950 for the 5-day course (five single-use packets). Many commercial insurers cover it with prior authorization, typically requiring documentation of at least 4-6 AK lesions on the face or scalp and failure or intolerance of one prior field therapy (usually 5-FU or imiquimod). Medicare Part D formularies vary; some list it on tier 3, others require step therapy [15].

Among the retinoids, adapalene 0.1% gel is the most accessible at roughly $10-15 OTC for a 45g tube. Generic tretinoin cream (0.025-0.05%) costs $30-80 with a GoodRx-type coupon. Brand-name tazarotene (Tazorac) and trifarotene (Aklief) are more expensive, ranging from $400-700 without insurance, though manufacturer copay cards often reduce out-of-pocket costs to $25-75 per month for commercially insured patients.

The 5-day treatment duration for tirbanibulin means the total drug cost is a one-time expense per treatment cycle, unlike retinoids which require ongoing monthly purchases. For patients with recurrent AK, retreatment with tirbanibulin at a later date may be necessary. Current data do not include long-term recurrence rates beyond 12 months post-treatment, which remains an open question in the literature.

Patients starting tirbanibulin should apply the ointment once daily to the affected area for 5 consecutive days, wash hands immediately after application, and avoid occlusive dressings over the treated site. Treatment-area skin reactions are expected and do not require discontinuation unless severe erosion or secondary infection develops [1].